Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Indian Pediatr ; 2016 Apr; 53(4): 290-291
Article in English | IMSEAR | ID: sea-178950
3.
Indian Pediatr ; 2011 Mar; 48(3): 249
Article in English | IMSEAR | ID: sea-168803
4.
Indian J Pediatr ; 2010 Nov ; 77 (11): 1326-1328
Article in English | IMSEAR | ID: sea-157183

ABSTRACT

A 5 1/2-yr-old boy presented with high grade fever for 4 days, and cervical adenitis, body ache, arthralgia, followed by sudden onset of breathlessness. He had clinical, electrocardiographic and echo evidence of myocarditis and congestive cardiac failure. An enzymelinked immunosorbent assay (MAC-IgM ELISA) with serum collected 5 days after disease onset showed IgM antibodies to CHIKV. He was managed conservatively and started showing symptomatic improvement by 3 days. At discharge, a repeat Echocardiogram (a week later) showed normal left ventricular (LV) function with mild Mitral regurgitation. On follow up, after 2 months, child remains asymptomatic. Other common aetiological agents were screened for and found negative. This may indicate a probable cardiac tropism for the virus.

6.
Indian Pediatr ; 2010 Jan; 47(1): 67-73
Article in English | IMSEAR | ID: sea-168384

ABSTRACT

Objective: To compare the effectiveness of intermittent with daily chemotherapy (both containing rifampicin) in childhood tuberculosis (age ≤16yrs) in achieving cure/ significant improvement. Design: Systematic Review and Meta-analysis. Methods: MEDLINE and the Cochrane Library were searched for randomized trials of antitubercular regimens containing rifampicin, in children 16 yrs or less with tuberculosis. Two reviewers independently assessed trial eligibility and quality. Data from full articles of selected studies were independently extracted by two authors and analyzed. The odds ratio was obtained for the pooled data in two groups (intermittent and daily therapy). Outcome variables: Cure/significant improvement, relapse rate and adverse events. Results: Four randomized controlled trials comparing twice weekly and daily therapy including 466 children (pulmonary 439; extrapulmonary 27) met the inclusion criteria. Baseline data were comparable. On quality assessment, 3 studies scored 2 and one study scored 3 out of 5 points. Per protocol analysis showed that children receiving intermittent regimen were less likely to be cured than those receiving daily therapy (OR 0.27; 95% CI: 0.14, 0.51). The results of intention to treat analysis suggest similar trend towards lower cure rates with twice weekly regimen (OR 0.66; 95% CI: 0.23-1.84). Conclusion: Twice weekly intermittent short course therapy is less likely to cure tuberculosis in children as compared to daily therapy. There is a need for better quality randomized controlled trials for assessing efficacy of alternate schedule for intermittent therapy for childhood tuberculosis.

7.
Indian Pediatr ; 2008 Oct; 45(10): 852-4
Article in English | IMSEAR | ID: sea-11795

ABSTRACT

The Revised National Tuberculosis Control Program (RNTCP) has initiated provision of antitubercular therapy for children with strategy of patient-wise boxes for the 4 different weight bands (6- 10 kg; 11- 17 kg; 18- 25 kg; 26- 30 kg). We evaluated the dose of individual drugs delivered by this approach to children of varying weights. The following areas of concern were identified: underdosing of individual antitubercular drugs for many weights; lack of provision to modify doses when child gains weight and moves to another weight band; and, inappropriate formulations, particularly for infants. We conclude that the current dosing strategy used in RNTCP needs modification to prevent the significant risk of underdosing and undertreatment.


Subject(s)
Antitubercular Agents/administration & dosage , Body Weight , Clinical Protocols , Communicable Disease Control/organization & administration , Humans , India , National Health Programs , Tuberculosis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL